Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$617.00K$617.00Kderived−0.2% vs Q4 2017 Net Income-$2.93M-$2.93MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,150,000N/M Operating Cash Flowderived-$4,648,000N/M Free Cash Flowderived-$4,650,000N/M Margins · derivedOperating margin-510.5%−48.9 pt vs Q4 2017
Net margin-474.2%−38.0 pt vs Q4 2017
ended Aug 31, 2018 · filed Nov 28, 2018 · 89 d after period end